Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CX1440 capsules in relapsed or refractory B-cell malignancies
ChiCTR2000031249Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bangsaitinib in B-cell malignancy, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL) and 5 more (8 cohorts), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Maximum tolerated dose and Dose-limiting toxicity. Started Jan 2020; status: recruiting.
02
Drugs
bangsaitinib
03
Conditions
B-cell malignancychronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on ChiCTR2000031249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031249.